Neoplasms

All Conditions

Digestive System Diseases

Symptoms and General Pathology

Carcinoma

Carcinoma, Hepatocellular

Liver Cirrhosis

Liver Neoplasms

Fibrosis

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Hematinics

All Drugs and Chemicals

Liver Extracts

The patients in this arm will receive Sirsphere trans-arterial radioembolization before surgery

Patients will receive Sirsphere trans-arterial radioembolization before surgery

Sirsphere trans-arterial radioembolization

Alain Hendlisz, MD

Vincent Donckier, MD, PHD

The purpose of this study is to assess the safety of transarterial radioembolization prior to surgical resection or radiofrequency in cirrhotic patients with hepatocellular carcinoma

The purpose of this study is to assess the peri-operative morbidity and mortality of supraselective ablative transarterial radioembolization prior to surgical resection or radiofrequency in cirrhotic patients with HCC

Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver

Treatment With Yttrium90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver

peri-operative morbidity of supraselective ablative transarterial radioembolization prior to surgical resection or radiofrequency in cirrhotic patients with HCC (starting from date of inclusion till 90 days after surgery or hospital discharge if more than 90 days)

Assessment of the overall disease free survival and Overall Survival

Estimation of disease free survival and overall survival rates after 1 and 3 years

Assessment of tumour size regression after Trans-arterial radioembolization by MRI

Assessment of imaging parameters changes (DW-MRI, FDG-PET/CT) and MAA-SPECT-CT in relation to the outcome measured by tumour regression after TARE, disease free and overall survival.

Assessment of TARE induced liver contralateral lobe hypertrophy (volumetric measurement by MRI).

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver	NCT01686880	Hepatocellular ... Liver Cirrhosis	Sirsphere trans...	18 Years -	Jules Bordet Institute
Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver	NCT01686880	Hepatocellular ... Liver Cirrhosis	Sirsphere trans...	18 Years -	Jules Bordet Institute

Spots Global Cancer Trial Database for sirspheres

Every month we try and update this database with for sirspheres cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for sirspheres

Every month we try and update this database with for sirspheres cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for sirspheres cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.